Lipidomics Market size is anticipated to be valued at USD 50.0 million in 2021 and is expanded to grow at a significant CAGR of 8.0% over 2022-2028. Lipidomics is a growing field of biomedical study that encompasses lipidome analysis. It’s a complete and quantitative description of a collection of lipid species found in an organism. The worldwide lipidomics market is predicted to benefit from a wide range of lipidomics applications, as well as an increase in the prevalence of target diseases such as malignancies and the breadth of clinical trials and toxicological investigations. During the forecast period, the Lipidomics market is expected to rise rapidly. Novel technology approvals, as well as other organic growth tactics such as patents and events, are being prioritized by a lot of companies. Acquisitions, as well as collaborations and partnerships, were considered inorganic growth tactics in the market. These activities have paved the way for the expansion of business and the customer base of market players. The rise in need for precise illness diagnosis, demand for tailored therapy, and technological breakthroughs in lipidomics are propelling the lipidomics market forward. Growth is attributed to meeting the requirements of aging populations and infants, and the prevalence of chronic diseases and changing food habits contribute to the intake of supplements and energy-providing food are boosting the global lipidomics market. In the forecast period of 2021-2028, rising raw material and technology costs are expected to pose a challenge to the lipid market. Over the anticipated period, the market is expected to rise due to an increase in the demand for precise illness diagnosis, growth in demand for personalized treatment, technological advancements in the field of lipidomics, and large investments from the public and commercial sectors in R&D activities.
In July 2020, Croda International Plc (‘Croda’) confirms that, following approval from the US regulatory authorities, it has now successfully completed the acquisition of Avanti Polar Lipids, Inc., a leader in drug delivery systems for next generation pharmaceuticals.
In March 2020, Waters Corporation and the University of Tokyo are collaborating on a lipidomics research project to provide a clearer picture of what it means to be healthy. Led by Prof. Yoshiya Oda from the Graduate School of Medicine at the University of Tokyo, the study is exploring the relationship between lipids and human health through the application of ion mobility-mass spectrometry (IMS-MS) technology.